Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
30 Julho 2024 - 10:00AM
Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a
pioneering force in medical aesthetics, announced the appointment
of Orian Shirihai, MD, PhD, to the Scientific Advisory Board of its
subsidiary, Elevai Biosciences Inc. (“Elevai Biosciences”). As a
renowned researcher in the field of metabolism, Dr. Shirihai will
support the advancement of EL-22, a first-in-class engineered
probiotic approach, to address obesity’s pressing issue of
preserving muscle while on weight loss treatments, including GLP-1
receptor agonists.
“Dr. Shirihai is recognized as a leader in endocrinology
research, with deep expertise in metabolism and obesity,”
said Dr. Jordan R. Plews, PhD, Chief Executive Officer of
Elevai Biosciences. “His knowledge, as well as broad network in the
space, will help us to develop our lead clinical candidate EL-22 as
a differentiated, oral myostatin approach for obese patients who
need to preserve muscle while losing fat. We know Dr. Shirihai will
be a valuable asset as we further develop EL-22 and EL-32."
Orian Shirihai, MD, PhD, is currently a Professor of Medicine at
the University of California, Los Angeles (UCLA) where he serves as
Director of the UCLA Metabolism Research Theme. The Shirihai
laboratory focuses on mitochondrial structure, function and quality
control, making key contributions to mitochondrial biology
including the discovery of the life cycle of the mitochondria and
the relationship between mitochondrial architecture and nutrient
utilization in metabolic diseases. Another focus of the Shirihai
lab is the development of novel approaches for the study of
mitochondrial function and dynamics in metabolic diseases. Dr.
Shirihai received his MD and PhD from the Technion - Israel
Institute of Technology in 1997.
Elevai Biosciences expects to recruit additional distinguished
scientific leaders with vast experience in the field of metabolic
health and obesity to join its team.
Chief Executive Officer of Elevai Biosciences’ parent company,
Elevai Labs Inc., Graydon Bensler, comments: “I’m enthusiastic
about the current and future developments occurring at Elevai
Biosciences. As a growth-focused organization at Elevai Labs, we
are looking for more opportunities to increase shareholder value
through further strategic acquisitions and investments in the
biotech, cosmetic, health, and wellness spaces.”
About Elevai Labs, Inc.Elevai Labs Inc.
(NASDAQ: ELAB) specializes in medical aesthetics and
biopharmaceutical drug development, focusing on innovations for
skin aesthetics and treatments tied to obesity and metabolic
health. Driven by a commitment to scientific research, we aim to
transform personal health and beauty. For more information, please
visit www.elevailabs.com.
About Elevai BiosciencesElevai Biosciences
Inc., an Elevai Labs company, is a biopharmaceutical company
focusing on the development and acquisition of cutting-edge
aesthetic medicines. Our lead asset, EL-22, is leveraging a
first-in-class engineered probiotic approach to address obesity’s
pressing issue of preserving muscle while on weight loss
treatments, including GLP-1 receptor agonists. For more
information, please visit www.elevaibio.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Words such as “believes,” “expects,” “plans,”
“potential,” “would” and “future” or similar expressions such as
“look forward” are intended to identify forward-looking statements.
Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based
only on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy, activities
of regulators and future regulations and other future conditions.
Because forward-looking statements relate to the future, they are
subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results.
Therefore, you should not rely on any of these forward-looking
statements. These and other risks are described more fully in
Elevai’s filings with the Securities and Exchange Commission
(“SEC”), including the “Risk Factors” section of the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the SEC on March 29, 2024, and its other documents
subsequently filed with or furnished to the SEC. Investors and
security holders are urged to read these documents free of charge
on the SEC’s web site at www.sec.gov. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Except to the extent required by law,
the Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Media Contact:Makenzie
Manncontact@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Elevai Labs (NASDAQ:ELAB)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024